Literature DB >> 15174009

Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease.

Anthony E Lang, José A Obeso.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15174009     DOI： 10.1002/ana.20102

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  22 in total

Review 1.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 2.  Strengths and limitations of genetic mouse models of Parkinson's disease.

Authors:  Marie-Francoise Chesselet; Sheila Fleming; Farzad Mortazavi; Bernd Meurers
Journal:  Parkinsonism Relat Disord       Date:  2008-06-27       Impact factor: 4.891

Review 3.  Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Authors:  J A Obeso; M Stamelou; C G Goetz; W Poewe; A E Lang; D Weintraub; D Burn; G M Halliday; E Bezard; S Przedborski; S Lehericy; D J Brooks; J C Rothwell; M Hallett; M R DeLong; C Marras; C M Tanner; G W Ross; J W Langston; C Klein; V Bonifati; J Jankovic; A M Lozano; G Deuschl; H Bergman; E Tolosa; M Rodriguez-Violante; S Fahn; R B Postuma; D Berg; K Marek; D G Standaert; D J Surmeier; C W Olanow; J H Kordower; P Calabresi; A H V Schapira; A J Stoessl
Journal:  Mov Disord       Date:  2017-09       Impact factor: 10.338

4.  Do patient's get angrier following STN, GPi, and thalamic deep brain stimulation.

Authors:  Adam P Burdick; Kelly D Foote; Samuel Wu; Dawn Bowers; Pam Zeilman; Charles E Jacobson; Herbert E Ward; Michael S Okun
Journal:  Neuroimage       Date:  2010-10-04       Impact factor: 6.556

5.  Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial.

Authors:  Michael S Okun; Hubert H Fernandez; Samuel S Wu; Lindsey Kirsch-Darrow; Dawn Bowers; Frank Bova; Michele Suelter; Charles E Jacobson; Xinping Wang; Clifford W Gordon; Pam Zeilman; Janet Romrell; Pam Martin; Herbert Ward; Ramon L Rodriguez; Kelly D Foote
Journal:  Ann Neurol       Date:  2009-05       Impact factor: 10.422

Review 6.  Non-dopaminergic treatments for motor control in Parkinson's disease.

Authors:  Susan H Fox
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

7.  In vivo electrophysiology of nigral and thalamic neurons in alpha-synuclein-overexpressing mice highlights differences from toxin-based models of parkinsonism.

Authors:  C J Lobb; A K Zaheer; Y Smith; D Jaeger
Journal:  J Neurophysiol       Date:  2013-09-25       Impact factor: 2.714

Review 8.  Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots.

Authors:  Shao-Hua Yang; Wenjun Li; Nathalie Sumien; Michael Forster; James W Simpkins; Ran Liu
Journal:  Prog Neurobiol       Date:  2015-11-18       Impact factor: 11.685

9.  Parkinson's disease brain mitochondria have impaired respirasome assembly, age-related increases in distribution of oxidative damage to mtDNA and no differences in heteroplasmic mtDNA mutation abundance.

Authors:  Charles R Arthur; Stephanie L Morton; Lisa D Dunham; Paula M Keeney; James P Bennett
Journal:  Mol Neurodegener       Date:  2009-09-23       Impact factor: 14.195

10.  Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice.

Authors:  Francisco Pan-Montojo; Oleg Anichtchik; Yanina Dening; Lilla Knels; Stefan Pursche; Roland Jung; Sandra Jackson; Gabriele Gille; Maria Grazia Spillantini; Heinz Reichmann; Richard H W Funk
Journal:  PLoS One       Date:  2010-01-19       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.